Literature DB >> 29396032

Pound foolish and penny wise-when will dosing of rifampicin be optimised?

Cecile Magis-Escurra1, Richard M Anthony2, Adri G M van der Zanden3, Dick van Soolingen2, Jan-Willem C Alffenaar4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29396032     DOI： 10.1016/S2213-2600(18)30044-4

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  5 in total

1.  Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.

Authors:  Paolo Denti; Roeland E Wasmann; Annelies van Rie; Jana Winckler; Adrie Bekker; Helena Rabie; Anneke C Hesseling; Louvina E van der Laan; Carmen Gonzalez-Martinez; Heather J Zar; Gerry Davies; Lubbe Wiesner; Elin M Svensson; Helen M McIlleron
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

2.  Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

Authors:  Sander P van Rijn; Marlanka A Zuur; Richard Anthony; Bob Wilffert; Richard van Altena; Onno W Akkerman; Wiel C M de Lange; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.

Authors:  Charlotte Seijger; Wouter Hoefsloot; Inge Bergsma-de Guchteneire; Lindsey Te Brake; Jakko van Ingen; Saskia Kuipers; Reinout van Crevel; Rob Aarnoutse; Martin Boeree; Cecile Magis-Escurra
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

4.  Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.

Authors:  Blessed Winston Aruldhas; Richard M Hoglund; Jaya Ranjalkar; Joel Tarning; Sumith K Mathew; Valsan Philip Verghese; Anuradha Bose; Binu Susan Mathew
Journal:  Br J Clin Pharmacol       Date:  2019-01-17       Impact factor: 4.335

5.  Recurrent Tuberculosis Disease in Singapore.

Authors:  Suay Hong Gan; Kyi Win KhinMar; Li Wei Ang; Leo K Y Lim; Li Hwei Sng; Yee Tang Wang; Cynthia B E Chee
Journal:  Open Forum Infect Dis       Date:  2021-06-27       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.